Cabergoline versus levodopa monotherapy.
Wheatley
Keith
K
Clarke
Carl E
CE
Ives
Natalie
N
Gray
Richard
R
D000978:Antiparkinson Agents / Q000191:economics / Q000627:therapeutic use*; D000077465:Cabergoline; D003362:Cost-Benefit Analysis; D004873:Ergolines / Q000191:economics / Q000627:therapeutic use*; D006801:Humans; D007980:Levodopa / Q000191:economics / Q000627:therapeutic use*; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy* / Q000191:economics
D000978:Antiparkinson Agents; D004873:Ergolines; D007980:Levodopa; D000077465:Cabergoline